HHS RELABELS INVALIDATED 340B REGULATION AS “INTERPRETATIVE RULE”

Earlier this week HHS came out swinging in the latest round of its battle with the Pharmaceutical Research & Manufacturers of America (PhRMA) over the Affordable Care Act’s provisions on 340B and orphan drugs.  HHS reasserted its long-held position on its website, this time calling it an “interpretative …

[Read more...]

HHS POISED FOR ROUND TWO OF ORPHAN DRUG FIGHT

HHS isn’t ready to throw in the towel in the fight over expansion of the 340B program under the Affordable Care Act (ACA).  On Thursday HHS said in a court filing that it will appeal last month’s federal court ruling that struck down a regulation issued by the Health Resources & Services …

[Read more...]

FEDERAL COURT INVALIDATES 340B ORPHAN DRUG REGULATION

Last Friday a federal district court invalidated a regulation that had authorized the 340B discount for critical access hospitals, sole community hospitals, rural referral centers and free-standing cancer hospitals when they purchase orphan drugs for off-label purposes. Two concepts are necessary for …

[Read more...]